Insights from ESMOGI24 by Angela Lamarca
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a few updates on this conference:
Data on tools for Early Diagnosis of HCC presented at ESMOGI24
AI and BIGDATA (Routine-blood AI) coming to help and beating our old friend AFP:
- more sensible
- better adherence
- validation required… but so far so good.
Subgroup analysis on NETTER2 with PRRT vs high dose SSA in high Ki67.
NETs CONFIRMS activity in
- G2 and G3
- Pancreas and Small Bowel
Lowest ORR in Small Bowel, Short time to response, Patient selection (not chemo patients).
MINOTAUR trial
- Presented by Elisa Fontana at ESMOGI24
- PKMYT1 inhibitor plus FOLFIRI in CCNE1 amplified and FBXW7 mutated GI Cancers (Biliary, Pancreas and NET included.
KRAS in Gastrointestinal Cancers
Fantastic Keynote Lecture on targeting KRAS in Gastrointestinal Cancers by in ESMOGI24 by Ryan Corcoran.
90% of PDAC are KRAS mutant.
